Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Possible Impact of Merck Acqusition of Cubist on the Trius CVR

I was just asked about the potential impact on the value of the Trius CVR of the Merck acquisition of…
Read more…

Trius: Will there be a Higher Bidder and what is the CVR Worth? (TSRX; $14.10)

What is the CVR Worth?
I wanted to address some additional points in regard to the proposed acquisition of Trius (TSRX)…
Read more…

Trius Therapeutics to be Acquired by Cubist (TSRX: $13.66)

Implications for Trius Shareholders
Cubist Pharmaceuticals (CBST) and Trius Therapeutics, Inc. (TSRX) announced that they have signed a definitive agreement under…
Read more…

Thoughts on the Growing Crisis of Bacterial Resistance to Antibiotics

Investment Overview
We hear constantly from the media about problems with bacterial resistance to antibiotics. I think that this is an…
Read more…

SmithOnStocks Opines on Stocks May 19, Edition

One Approach for Investing in Emerging Biotechnology Stocks
I write on biotechnology and pharmaceutical companies of all sizes, but I have…
Read more…

Trius Therapeutics: Newly Allowed Patent Provides Important New Dimension to Investment Outlook (TSRX, $8.50)

Investment Thesis

Trius announced an important new development today that bolsters my investment case for Trius (TSRX) and I continue with…
Read more…

Trius: Clinical Trials Show Important Differentiation of Tedizolid from Zyvox (TSRX, $6.48)

Investment Summary and Opinion
I attended Trius' (TSRX) CEO Jeff Stein's presentation at the BioCentury Conference in New York on April…
Read more…

Trius: Topline Data of Second Phase III Trial of Tedizolid is Eminent (TSRX, $6.76)

Investment Summary and Conclusion

I began recommending Trius (TSRX) with an initiation of coverage report that was published in May of…
Read more…

Trius: Why Last Friday’s Equity Offering is good for the Stock (TSRX, $4.90)

Investment Opinion

Trius (TSRX) completed an equity offering on Friday January 19 in which it sold 6.3 million shares at $4.465.…
Read more…

Trius Therapeutics: In an About Face, Congress is Helping Biotech Companies That Are Developing Antibiotics (TSRX, $5.54)

Investment Opinion
In this report, I present my hypothesis as to why I believe that antibiotics development is in the rapid…
Read more…

Settlement Between Pfizer and Teva on Generic Zyvox is a Significant Positive for Trius Therapeutics

The Issue
On May 31, 2012, Pfizer Inc. (PFE) and Teva (TEVA reached a settlement that licenses to Teva a generic…
Read more…

An Update on Trius Therapeutics’ Tedizolid; a Potential Blockbuster for Treating MRSA Infections (TSRX, $5.41)

 

I am reiterating my buy recommendation on Trius Therapeutics (NASDAQ: TSRX). This note is follow-up to a 35 page report…
Read more…

An Update on Trius Therapeutics’ Tedizolid; a Potential Blockbuster for Treating MRSA Infections (TSRX, $5.41)

Investment Recommendation
I am reiterating my buy recommendation on Trius Therapeutics (NASDAQ: TSRX). This note is follow-up to a 35 page…
Read more…

Trius Therapeutics' Tedizolid has Blockbuster Potential for MRSA Infections (TSRX, $5.05)

Introduction Trius Therapeutics is in late stage clinical development of its new antibiotic, tedizolid, for treatment of MRSA infections that…
Read more…

Trius' (TSRX) Tedizolid Has Blockbuster Potential for MRSA Infections

Trius Therapeutics TSRX) is in late stage clinical development of its new antibiotic, tedizolid, for treatment of MRSA infections that…
Read more…